Xiao-hui Zhai1, Jie-kai Yu, Chen Lin, Li-dong Wang, Shu Zheng. 1. Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China.
Abstract
OBJECTIVE: Biomarker assay is a noninvasive method for the early detection of esophageal squamous cell carcinoma (ESCC). Searching for new biomarkers with high specificity and sensitivity is very important for the early detection of ESCC. Serum surface-enhanced laser desorption/ionization-time of flight mass spectrometry (SELDI-TOF-MS) is a high throughput technology for identifying cancer biomarkers using drops of sera. METHODS: In this study, 185 serum samples were taken from ESCC patients in a high incidence area and screened by SELDI. A support vector machine (SVM) algorithm was adopted to analyze the samples. RESULTS: The SVM patterns successfully distinguished ESCC from pre-cancerous lesions (PCLs). Also, types of PCL, including dysplasia (DYS) and basal cell hyperplasia (BCH), and healthy controls (HC) were distinguished with an accuracy of 95.2% (DYS), 96.6% (BCH), and 93.8% (HC), respectively. A marker of 25.1 kDa was identified in the ESCC patterns whose peak intensity was observed to increase significantly during the development of esophageal carcinogenesis, and to decrease obviously after surgery. CONCLUSIONS: We selected five ESCC biomarkers to form a diagnostic pattern which can discriminate among the different stages of esophageal carcinogenesis. This pattern can significantly improve the detection of ESCC.
OBJECTIVE: Biomarker assay is a noninvasive method for the early detection of esophageal squamous cell carcinoma (ESCC). Searching for new biomarkers with high specificity and sensitivity is very important for the early detection of ESCC. Serum surface-enhanced laser desorption/ionization-time of flight mass spectrometry (SELDI-TOF-MS) is a high throughput technology for identifying cancer biomarkers using drops of sera. METHODS: In this study, 185 serum samples were taken from ESCC patients in a high incidence area and screened by SELDI. A support vector machine (SVM) algorithm was adopted to analyze the samples. RESULTS: The SVM patterns successfully distinguished ESCC from pre-cancerous lesions (PCLs). Also, types of PCL, including dysplasia (DYS) and basal cell hyperplasia (BCH), and healthy controls (HC) were distinguished with an accuracy of 95.2% (DYS), 96.6% (BCH), and 93.8% (HC), respectively. A marker of 25.1 kDa was identified in the ESCC patterns whose peak intensity was observed to increase significantly during the development of esophageal carcinogenesis, and to decrease obviously after surgery. CONCLUSIONS: We selected five ESCC biomarkers to form a diagnostic pattern which can discriminate among the different stages of esophageal carcinogenesis. This pattern can significantly improve the detection of ESCC.
Authors: Alex J Rai; Zhen Zhang; Jason Rosenzweig; Ie-Ming Shih; Thang Pham; Eric T Fung; Lori J Sokoll; Daniel W Chan Journal: Arch Pathol Lab Med Date: 2002-12 Impact factor: 5.534
Authors: H Kawaguchi; S Ohno; M Miyazaki; K Hashimoto; A Egashira; H Saeki; M Watanabe; K Sugimachi Journal: Cancer Date: 2000-10-01 Impact factor: 6.860
Authors: Bao-Ling Adam; Yinsheng Qu; John W Davis; Michael D Ward; Mary Ann Clements; Lisa H Cazares; O John Semmes; Paul F Schellhammer; Yutaka Yasui; Ziding Feng; George L Wright Journal: Cancer Res Date: 2002-07-01 Impact factor: 12.701
Authors: Annemieke W J Opstal-van Winden; Esmeralda J M Krop; Monica H Kåredal; Marie-Christine W Gast; Christian H Lindh; Marina C Jeppsson; Bo A G Jönsson; Diederick E Grobbee; Petra H M Peeters; Jos H Beijnen; Carla H van Gils; Roel C H Vermeulen Journal: BMC Cancer Date: 2011-08-26 Impact factor: 4.430